STOCK TITAN

Oncolytics Biotech opts for 3-year say-on-pay votes

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Oncolytics Biotech Inc. (ONCY) reported outcomes from its November 19, 2026 annual meeting. Stockholders elected seven directors to serve until the 2027 annual meeting and approved the advisory vote on named executive officer compensation. The accounting-firm appointment was ratified, although the meeting overview names Baker Tilly US, LLP while the Proposal 2 results heading names KPMG LLP. Of 131,120,719 common shares outstanding on the record date, holders representing 65,061,822 votes, or 49.61%, were represented. The one-year compensation-vote option received the most votes (11,319,330, compared with 9,781,900 for three years). The board said it will hold the advisory vote every three years unless it determines another frequency is in stockholders’ best interest.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Common shares outstanding 131,120,719 shares On the annual meeting record date
Votes represented 65,061,822 votes (49.61%) Annual meeting; the company reported this constituted a quorum
Directors elected 7 directors Terms run until the 2027 annual meeting
Accounting-firm proposal votes for 62,887,796 votes Proposal 2 results
Say-on-compensation votes for 13,559,766 votes Advisory vote on named executive officer compensation
Say-on-compensation votes against 9,777,095 votes Advisory vote on named executive officer compensation
One-year frequency option 11,319,330 votes Advisory vote frequency proposal
Three-year frequency option 9,781,900 votes Advisory vote frequency proposal
quorum regulatory
"constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Broker Non-Votes regulatory
"Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
named executive officers regulatory
"compensation of the Company’s named executive officers"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
advisory vote regulatory
"advisory vote on the frequency"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who was elected to ONCY’s board at the 2026 annual meeting?

All seven director nominees were elected: Jared Kelly, Bernd R. Seizinger, Deborah M. Brown, James T. Parsons, Jonathan Rigby, Patricia S. Andrews and Stephen Glover. Their terms run until the 2027 annual meeting.

How did ONCY shareholders vote on the frequency of executive compensation votes?

The one-year option received the most votes, with 11,319,330, compared with 9,781,900 for three years. The board said it will hold the advisory vote every three years unless it later determines another frequency is in stockholders’ best interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001129928 0001129928 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 19, 2026

 

 

 

Oncolytics Biotech Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada 001-38512 98-0541667
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

4350 Executive Drive, Suite 325

San Diego, CA 92121

92121
(Address of principal executive offices) (Zip Code)
   
(403) 670-7377
(Registrant's telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Common stock, par value $0.001 per share   ONCY   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On November 19, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) at 4:00 p.m. Eastern Time by means of an online virtual meeting platform. There were 131,120,719 shares of common stock outstanding on the record date. Stockholders representing 65,061,822, or 49.61%, of the 131,120,719 votes outstanding were represented in person or by proxy constituting a quorum.

 

At the 2026 Annual Meeting, the following proposals were approved: (i) the election of seven directors to hold office until the 2027 annual meeting; (ii) the ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026; and (iii) the advisory vote on the compensation of the Company’s named executive officers. The Board’s recommendation to hold the advisory frequency vote on the compensation of the Company’s named executive officers every three years did not receive a majority of the votes cast. The Board values the opinion of the Company’s stockholders and has taken into consideration the recommendation of the Company’s stockholders to hold an advisory vote on executive compensation every year. After consideration, the Board has determined, and believe it to be in the best interest of the Company, to hold an advisory vote on executive compensation every three years, or until the Board otherwise determines that a different frequency for such advisor vote is in the best interest of the stockholders of the Company. These proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the SEC on October 6, 2026.

 

Proposal 1

 

The votes with respect to the election of seven directors to hold office until the 2027 annual meeting were as follows:

 

Director  For   % Voted For   Withheld   % Voted
Withheld
   Broker Non-
Votes
 
Jared Kelly   21,465,185    89.54%   2,508,575    10.46%   41,088,062 
Bernd R. Seizinger   21,380,239    89.18%   2,593,521    10.82%   41,088,062 
Deborah M. Brown   21,572,684    89.98%   2,401,076    10.02%   41,088,062 
James T. Parsons   20,724,255    86.45%   3,249,505    13.55%   41,088,062 
Jonathan Rigby   21,506,444    89.71%   2,467,316    10.29%   41,088,062 
Patricia S. Andrews   21,669,279    90.39%   2,304,481    9.61%   41,088,062 
Stephen Glover   21,624,838    90.20%   2,348,922    9.80%   41,088,062 

 

Proposal 2

 

The votes with respect to the ratification of KPMG LLP as the Company’s independent registered accounting firm for the year ending December 31, 2026, were as follows:

 

Total Votes For  Total Votes Against   Abstentions   Broker Non-Votes 
62,887,796   1,694,520    479,506    - 

 

 

 

Proposal 3

 

The votes with respect to the advisory vote to approve the compensation of the Company’s named executive officers were as follows:

 

Total Votes For  Total Votes Against   Abstentions   Broker Non-Votes 
13,559,766   9,777,095    636,899    41,088,062 

 

Proposal 4

 

The votes with respect to the advisory vote on the frequency of the advisory vote on the compensation of the Company’s named executive officers were as follows:

 

3 Years  2 Years   1 Year   Abstentions   Broker Non-Votes 
9,781,900   1,485,942    11,319,330    1,386,588    - 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 20, 2026

 

  ONCOLYTICS BIOTECH INC.
   
  By: /s/ Kirk Look
  Name: Kirk Look
  Title: Chief Financial Officer

 

 

Filing Exhibits & Attachments

3 documents

Keep reading